Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 4, 2025 • 12:40 PM ET

Date/Time Source News Release
06/26/2025 08:00 AM EDT GlobeNewswire BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
06/24/2025 04:05 PM EDT GlobeNewswire BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
05/15/2025 08:00 AM EDT GlobeNewswire BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
05/14/2025 07:30 AM EDT GlobeNewswire BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
05/07/2025 08:00 AM EDT GlobeNewswire BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)
05/05/2025 08:00 AM EDT GlobeNewswire BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
04/16/2025 08:00 AM EDT GlobeNewswire BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled
03/27/2025 08:00 AM EDT GlobeNewswire BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
11/20/2024 08:00 AM EST GlobeNewswire BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
11/04/2024 08:00 AM EST GlobeNewswire BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded
Page

Additional News

As of July 4, 2025 • 12:40 PM ET

Date/Time Source News Release
05/13/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 13th, 2025
05/13/2025 05:30 AM EDT US Earnings Reports Expected earnings - BioVie Inc.
03/10/2025 11:35 AM EDT ACCESS Newswire IA New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI)
02/10/2025 06:00 AM EST US Earnings Reports Expected US Company Earnings on Monday, February 10th, 2025
02/10/2025 04:30 AM EST US Earnings Reports Expected earnings - BioVie Inc.
01/26/2025 10:00 AM EST ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation
01/22/2025 10:00 AM EST ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect
01/19/2025 10:00 AM EST ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out
01/15/2025 10:00 AM EST ACCESSWIRE IA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation
01/12/2025 10:00 AM EST ACCESSWIRE IA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation
Page